SuperGen Reports Preliminary Results For Phase Ib Data Of MP-470

SuperGen has reported preliminary results from phase Ib data of MP-470, tyrosine kinase and RAD51 suppressor. The results demonstrated an overall clinical benefit rate of 54%, when the drug is given in combination with standard of care carboplatin containing doublet chemotherapy, in patients with small cell lung cancer (SCLC) and neuroendocrine malignancies (NE).

However, as measured by the Response Evaluation Criteria in Solid Tumors (RECIST), five of 13 patients achieved a confirmed partial response, and two additional patients demonstrated stable disease greater than twelve weeks for an overall clinical benefit rate of 7/13 patients (or 54%).

Mohammad Azab, CMO at SuperGen, said: “We continue to be encouraged by the clinical data resulting from our MP-470 trials and the potential benefit of its addition to standard of care treatment regimens.

“We are looking forward to completing enrollment and analysis of the full data set from this trial to guide our partnering discussions and future phase II clinical development efforts for this promising novel agent,” he added.